EyeControl: A Communication Solution for Ventilated ICU Patients and Locked-in Individuals

Grant number: 961050

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $2,518,897.62
  • Funder

    European Commission
  • Principal Investigator

    RETZKIN Or
  • Research Location

    Israel
  • Lead Research Institution

    EYEFREE ASSISTING COMMUNICATION LTD
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management
  • Research Subcategory

    Supportive care, processes of care and management
  • Special Interest Tags

    N/A
  • Study Type

    Clinical
  • Clinical Trial Details

    Unspecified
  • Broad Policy Alignment

    Pending
  • Age Group

    Unspecified
  • Vulnerable Population

    Unspecified
  • Occupations of Interest

    Unspecified

Abstract

EyeFree Assisting Communication Ltd. developed the EyeControl, the first wearable, screenless assistive communication device. AI-powered eye-tracking technology enables communication between patients, medical staff and family, using only eye movements, without calibration or dependency on a screen or computer. EyeFree is changing reality, empowering autonomy among the Locked-in community by providing a round-the-clock communication solution that is operated independently by the user. EyeFree is expanding the scope of the recently finalized SME Phase 2 grant with the aim of developing additional improvements to the EyeControl technology, which will expedite medical facility market entry strategy. Short-term demand in this segment is growing; where an unmet need for communication in the ICU already existed, it has been further exasperated by an influx of ventilation caused by the Coronavirus. There is no solution on the market; and, that places the EyeControl at the forefront, as an immediate and effective assistive technology, facilitating easy and safe communication between patients, medical staff, caregivers, and families and leading to better quality patient care. Once this niche market has been consolidated, we will boost the market entry be known as the global communication platform for both ventilated and Locked-in patients, with two main product lines: EyeControl Home and Facility.